EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

An updated review on phytochemistry and molecular targets of Withania somnifera (L.) Dunal (Ashwagandha)

Arsalan Bashir, Masarat Nabi, Nahida Tabassum, Suhaib Afzal, Mehrose Ayoub

Frontiers in Pharmacology · 29.03.2023 · 14

DOI: 10.3389/fphar.2023.1049334 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.03.2023. Verfasst von Arsalan Bashir und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Kashmir, Srinagar, Jammu and Kashmir, India. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Withania somnifera (L.) Dunal belongs to the nightshade family Solanaceae and is commonly known as Ashwagandha. It is pharmacologically a significant medicinal plant of the Indian sub-continent, used in Ayurvedic and indigenous systems of medicine for more than 3,000 years. It is a rich reservoir of pharmaceutically bioactive constituents known as withanolides (a group of 300 naturally occurring C-28 steroidal lactones with an ergostane-based skeleton). Most of the biological activities of W. somnifera have been attributed to two key withanolides, namely, withaferin-A and withanolide-D. In addition, bioactive constituents such as withanosides, sitoindosides, steroidal lactones, and alkaloids are also present with a broad spectrum of therapeutic potential. Several research groups worldwide have discovered various molecular targets of W. somnifera , such as inhibiting the activation of nuclear factor kappa-B and promoting apoptosis of cancer cells. It also enhances dopaminergic D2 receptor activity (relief in Parkinson’s disease). The active principles such as sitoindosides VII-X and withaferin-A possess free radical properties. Withanolide-D increases the radio sensitivity of human cancer cells via inhibiting deoxyribonucleic acid (DNA) damage to non-homologous end-joining repair (NHEJ) pathways. Withanolide-V may serve as a potential inhibitor against the main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to combat COVID. The molecular docking studies revealed that the withanolide-A inhibits acetyl-cholinesterase in the brain, which could be a potential drug to treat Alzheimer’s disease. Besides, withanolide-A reduces the expression of the N-methyl-D-aspartate (NMDA) receptor, which is responsible for memory loss in epileptic rats. This review demonstrates that W. somnifera is a rich source of withanolides and other bioactive constituents, which can be used as a safe drug for various chronic diseases due to the minimal side effects in various pre-clinical studies. These results are interesting and signify that more clinical trials should be conducted to prove the efficacy and other potential therapeutic effects in human settings.

Schlagwörter

Stichwörter der Autor:innen

Withania somnifera (L.) Dunalapoptosismolecular targetsphytochemistrywithaferin Awithanolides

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University of Kashmir, Srinagar, Jammu and Kashmir, India.
  • Department of Environmental Science, University of Kashmir, Srinagar, Jammu and Kashmir, India.

Zitieren

APA

Bashir, A., Nabi, M., Tabassum, N., Afzal, S., & Ayoub, M. (2023). An updated review on phytochemistry and molecular targets of Withania somnifera (L.) Dunal (Ashwagandha). Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1049334

Vancouver

Bashir A, Nabi M, Tabassum N, Afzal S, Ayoub M. An updated review on phytochemistry and molecular targets of Withania somnifera (L.) Dunal (Ashwagandha). Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1049334

BibTeX
@article{Bashir2023,
  author = {Bashir, Arsalan and Nabi, Masarat and Tabassum, Nahida and Afzal, Suhaib and Ayoub, Mehrose},
  title = {An updated review on phytochemistry and molecular targets of Withania somnifera (L.) Dunal (Ashwagandha)},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1049334}
}
Kostenlos starten →